enrofloxacin solution
butler animal health supply, llc dba covetrus north america - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.
baytril tablet
elanco canada limited - enrofloxacin - tablet - 15mg - enrofloxacin 15mg - cats; dogs
floxabactin 15 mg tablets for cats and dogs
le vet b.v - enrofloxacin 15 mg - tablet - cats, dogs - enrofloxacin
enrotab 15 mg tablets for cats and dogs
le vet b.v - enrofloxacin 15 mg - tablet - cats, dogs - enrofloxacin
zobuxa 15 mg
novartis animal health uk limited - enrofloxacin 15 mg - tablet - cats, dogs - enrofloxacin
floxabactin 15 mg tablets for cats and dogs
le vet bv - enrofloxacin - tablets - 15 milligram - enrofloxacin - canine, feline - antibacterial
enrobactin 150 antibiotic tablets
dechra veterinary products (australia) pty. ltd. - enrofloxacin - oral tablet - enrofloxacin antibiotic active 150.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - abscess | bacterial infection | infections of the respiratory tract | infections of the skin | infections of upper respiratory tract | infectious sinusitis | wound infections | abscesses | acute respiratory infections | amoxycillin sensitive bacteria | anal sacculitis | associated with viral disease | bronchiseptica | bronchitis | discharging sinuses | fungal | gingivitis | gram negative bacteria | gram negative organisms | gram positive bacteria | gram positive organisms | pharyngitis | pneumonia | post parturient bacterial infe | post-parturient infections | primary bacterial infection | pyoderma | septicaemia | sulfadiazine sensitive bacteri | tonsillitis | trimethoprim sensitive bacteri | tylosin sensitive bacteria | yeast
enrobactin 50 antibiotic tablets
dechra veterinary products (australia) pty. ltd. - enrofloxacin - oral tablet - enrofloxacin antibiotic active 50.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - abscess | bacterial infection | infection of the genitourinary tract | infections of the skin | infections of upper respiratory tract | infectious sinusitis | wound infections | abscesses | amoxycillin sensitive bacteria | anal sacculitis | associated with viral disease | discharging sinuses | fungal | gingivitis | gram negative bacteria | gram negative organisms | gram positive bacteria | gram positive organisms | post parturient bacterial infe | post-parturient infections | primary bacterial infection | pyoderma | septicaemia | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria | yeast
enrotron flavour 50 mg tablets for dogs
animedica gmbh - enrofloxacin - tablet - 50 mg/tablet - enrofloxacin - dogs - antibacterial
baytril® (enrofloxacin) antibacterial injectable solution 2.27% for dogs only
bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar